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Abstract   
 
     Tumor heterogeneity is believed to be 
important in tumor progression and its 
response to therapies.  However, despite 
numerous mutations being reported in 
human tumors, genetic intra-tumor 
heterogeneity remains poorly defined.  
We have developed a novel strategy to 
provide a chronological annotation of 
mutational events in a tumor.  We used 
an endometrial tumor from a patient and 
transplanted it into athymic mice to create 
many tumor xenografts.  While the patient 
tumor xenografts were initially responsive 
to raloxifene treatment, xenografts 
created with cancer cell clones isolated 
from the same patient tumor showed 
dramatic differences in response to 
raloxifene, indicating existence of intra-
tumor heterogeneity with some 
subpopulations inherently resistant to the 
drug.  A 250K single nucleotide 
polymorphism (SNP) array from 
Affymetrix was used to profile genotype 
changes on 3 xenografts and 10 single 
cells from another 10 xenografts.  We 
found 797 SNP sites containing loss of 
heterozygosity (LOH) common to all 
these specimens, indicating that genetic 
mutations in these regions may contain 
the earliest genetic events in the original 
patient tumor.  Based upon the genotype 
information from the 10 single cancer 
cells, we developed a phylogenetic tree 
using neighbor-joining method.  We 
showed that there are at least 3 distinct 
subpopulations in the patient tumor.  
Additionally, the phylogenetic tree was 
used to determine the order of genetic 
events, thus providing a chronological 
annotation to genetic mutations.  Our 
approach represents an important 
analytic strategy for defining genetic intra-
tumor heterogeneity and providing 
chronological annotations to the genetic 
landscape revealed by future whole 
genome sequencing in tumors.   
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Introduction  
 
     Cancer is considered to be a genetic 
disease1 wherein an accumulation of 
genetic mutations allows cancer cells to 
acquire advantages for abnormal growth.  
Vogelstein et al. suggested a model of 
sequential genetic events involving 
several genes in colorectal cancer,2 
implicating a common mutational pathway 
among individual tumors.  Loeb et al. 
however suggested another model with 
mutations in DNA stability, leading to 
genetic instability as an early and critical 
event.3 The concept of genetic instability 
predicts enormous mutational 
heterogeneity in a tumor.  A systemic and 
complete documentation of genetic 
mutations in tumors, as Cancer Genome 
Anatomy Project proposes, is considered 
an essential approach to revealing the 
genetic basis of malignancy.  A pilot study 
recently demonstrated that there are on 
average 80-90 mutations in protein 
coding sequences in tumors.4,5  However, 
it is believed that only a small portion of 
them are responsible for cancer 
development.6,7  Interestingly, there 
seems to be no common pattern of 
genetic mutations in breast or colorectal 
tumors;6,7 each tumor presents its own 
distinct mutational profile.6  While whole 
genome sequencing in more tumors is 
necessary to establish a conclusive 
finding, these early results suggest that 
there may be several distinct pathways 
leading to oncogenesis among individual 
tumors of the same type.   
 
The existence of several distinct genetic 
pathways, herein genetic heterogeneity, 
may not only occur between tumors but 
may also be present within an individual 
tumor.  The concept of genetic intra-
tumor heterogeneity (GITH) has remained 
an interesting and unsettled research 
subject for decades.8,9  The potential for 
intra-tumor heterogeneity to metastasize 
was reported three decades ago.8 Distinct 
cancer cell subpopulations presented with 
unique karyotypes.9  It was proposed 
then that a neoplasm should not be 
considered as a uniform entity and that 
development of effective therapy should 
discriminate between distinct intra-tumor 
subpopulations.10  In 1984, Heppner 
proposed defining tumor heterogeneity as 
tumor cell differences existing distinctly 
as subpopulations with the capability to 
expand.11  Efforts have been made 
recently to define GITH through 
description of the differential distribution 
of genetic alterations inside a 
tumor.12,13,14  GITH has been 
demonstrated in different tumor regions 
12,13 and in cell populations separated by 
cell markers14 using several genetic 
analysis tools including microsatellite 
analysis, single nucleotide polymorphism 
(SNP) arrays and serial analysis of gene 
expression.  Losi et al. demonstrated that 
K-ras and p53 point mutations as well as 
loss of heterozygosity (LOH) on 
chromosomes 5q and 18q showed 
dramatic heterogeneity in their distribution 
within different regions of a tumor13.  
Interestingly, they reported that genetic 
heterogeneity inside a tumor decreases 
when tumors advance.13 A recent study 
by Khalique et al. using 53 SNP markers 
within 15 genes described a clonal 
relationship between different regions 
within tumors.12 Using LOH and 
microsatellite instability data, the authors 
compiled a parsimonious tree to study the 
evolutionary pattern of different regions 
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within each tumor.12  They came to a 
conclusion that ovarian cancers are 
monoclonal in origin.  Based upon distinct 
genetic features in cell subpopulations 
separated by surface markers CD24+ and 
CD44+, Shipitsin et al. made a molecular 
definition of breast tumor heterogeneity 
.14  These studies and others have 
demonstrated the heterogeneity of 
genetic alterations within a tumor through 
description of their distinct distribution in 
cancer cell subpopulations.  
Unfortunately, these studies have all 
missed one critical element of genetic 
alterations: a temporal description of 
genetic events.  Fundamental 
understanding of cancer biology – 
including the sequential accumulation of 
genetic alterations necessary for 
malignant transformation, tumor 
development through evolution and 
subsequent distant metastasis  – requires 
the annotation of genetic events with a 
time component, the chronological order 
of genetic alterations.  In addition, for the 
concept of GITH to have clinical 
relevance for prediction of cancer 
outcome or response to a therapy, a 
quantitative description of GITH is 
required.  For instance, it should be 
possible to address questions such as 
what percentage of cancer cells in a 
tumor contain a specific mutation, or how 
many distinct subpopulations exist in a 
tumor according to the presence or 
absence of a set of genetic mutations. 
We present here a study describing a 
strategy to dissect a tumor and 
reconstruct its evolutionary history.  
Genetic alterations in the whole genome 
of single cancer cell clones were 
interrogated.  GITH was defined through 
description of these alterations in distinct 
subpopulations.  Subsequently, 
mutational pathways of cancer cell clones 
were simultaneously generated through 
the construction of a phylogenetic tree.  
The genetic alterations common to all 
tumor specimens are hypothesized to be 
potential genetic events occurring in very 
early stages of carcinogenesis. 
 
Materials and Methods  
 
 1. Collection of patient tissues and 
creation of xenografts in athymic mice   
 
 Collection and use of human tumor 
specimens was approved by the Human 
Research Review Committees (HRRC) at 
the University of New Mexico Health 
Sciences Center.  The endometrial tumor 
was collected in cold sterile saline in the 
gross room of the Department of 
Pathology immediately after arrival from 
the operating room.  Animal use protocol 
was approved by the University of New 
Mexico Health Sciences Center 
Institutional Animal Care and Use 
Committee.  Six- to 8-week old female 
athymic Crl:NU/NU-nuBR mice were 
purchased from National Cancer Institute 
(Frederick, MD).  Fresh patient tumor 
specimens were rinsed with cold sterile 
phosphate buffered saline (PBS) and 
grossly necrotic tissue was trimmed 
away.  The tumor was minced and rinsed 
with PBS again.  Approximately 100mg of 
tumor suspended in 100µl Dulbecco's 
Modified Eagle's Medium (DMEM) was 
injected into athymic mice 
subcutaneously (sc) or intraperitoneally 
(ip).15,16  Xenografted tumors were 
harvested for tissue culture and extraction 
of genomic DNA.    
  
2. Animal treatment  
      
The xenografted tumors were measured 
weekly, and tumor cross-sectional areas 
(mm2) were calculated using the formula: 
length (mm) × width (mm) × /4.  
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Raloxifene (Eli Lilly, Indianapolis, IN) was 
given at 1.5mg/0.2ml/mouse through oral 
gavage daily (Monday through Friday) 
starting one week after tumor 
transplantation.  The control mice 
received saline accordingly.  Student’s t-
test was used to compare the size of 
tumors between the control and treatment 
groups.    
  
3. Tissue culture and clone selection  
 
Xenografts isolated from athymic mice 
were cultured and single cells were 
picked using a pipette under microscope.  
Genomic DNAs were extracted from one 
sc and 2 ip xenografts using the DNeasy 
Tissue Kit from QIAGEN (Valencia, CA).  
Ten DNA specimens from 10 single cells 
(each of them from one ip tumor) were 
also processed using a single-cell 
Omniplex whole genome amplification kit 
from Rubicon Genomics Inc. (Ann Arbor, 
MI).    
  
4. Creation of sequential generations 
of clonal cancer cells   
 
The endometrial cancer cell line Hec50co 
has been used in in vitro and in vivo 
studies, and was described 
previously.13,14,15,16,17  They were 
maintained in cell culture media, 
Dulbecco's Modified Eagle's Medium 
(DMEM), with 10% FBS.  Parental cells 
(designated as G0) were transferred to 
96-well plates at 1 cell/100μl/well for 
clonal separation.  The well with a single 
cell was spotted and allowed to reach 
subconfluence.  The cell population (from 
the single cell) was expanded to 30 
million.  Some of the cells were harvested 
to yield genomic DNA (designated G1) 
and the rest were transferred to 96-well 
plates at 1 cell/100μl/well.  Next 
generations (G2 and G3) were similarly 
created for harvest of genomic DNA.    
  
5. Whole Genome SNP Genotyping 
 
DNA samples were genotyped using the 
Affymetrix 250K Nsp Human Mapping 
GeneChip according to manufacturer’s 
protocol (Affymetrix, Santa Clara, CA).  
Briefly, 250 ng of genomic DNA was 
digested with Nsp and then ligated to 
adapters that recognize the cohesive four 
base-pair (bp) overhangs.  A generic 
primer that recognizes the adapter 
sequence was used to amplify adapter-
ligated DNA fragments with PCR 
conditions optimized to preferentially 
amplify fragments in the 250–2,000 bp 
size range in a MJ Research (Waltham, 
Massachusetts) PTC-225 Thermocycler. 
After purification with a Clontech DNA 
Amplication (Mountain View, CA) Clean-
up Kit, a total of 40 ug of PCR product 
was fragmented.  The fragmented DNA 
was then labeled with biotin and 
hybridized to the GeneChip Mapping 
250K Nsp GeneChip for 16 hr.  The 
arrays were washed and stained using 
the Affymetrix fluidics Station 450 and 
scanned the arrays using a GeneChip 
Scanner 3000 G7 (Affymetrix, Santa 
Clara, CA).  The Affymetrix GeneChip 
Operating Software (GCOS) collected 
and extracted feature data from the 
GeneChip Scanners.  Affymetrix 
GeneChip Genotyping analysis software 
(GTYPE) version 4.1 and ArrayAssist 
software (Stratagene/Agilent 
Technologies, Santa Clara , CA) were 
both used to analyze feature intensity 
data, determine genotype calls, and LOH 
for each of the 262,264 genomic SNPs.   
 
6. Generation of phylogenetic tree  
 
 We utilized the neighbor-joining (NJ) 
clustering method17 as implemented in 
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the Geneious bioinformatics software 
suite17 to reconstruct the phylogenetic 
tree.  The four possible SNP calls (AB, 
AA, BB, and no call) generated by the 
Affymetrix analysis software were 
mapped onto the two nucleotides A, C, C, 
and C, respectively.  Each clone was thus 
transformed into a ‘DNA’ character-state 
string or feature vector of equal length, 
which could then be processed by the 
phylogenetic methods supported by the 
Geneious software.  A Jukes-Cantor base 
substitution model18 was assumed.  This 
represents the simplest consistent 
mapping of SNPs to bases: each SNP 
call occurs with equal frequency, and all 
SNP substitutions occur at the same rate.  
NJ is a computationally-efficient 
(polynomial time) phylogenetic 
reconstruction methodology that has 
been shown to perform well in numerous 
tests.19  It is based on the minimum 
evolution criterion, and favors tree 
reconstructions for which the sum of the 
branch lengths (computed using a 
pairwise distance matrix) is minimized at 
each stage of the algorithm.17  The final 
reconstructed tree can be interpreted as a 
phylogeny (cf. the time scale in Fig. 3) 
because the branch lengths in the model 
correspond to evolutionary distances. 
 
 Results  
 
1. Development of tumor resistance to 
a therapy could be inherent in some 
cancer cells  
 
 We succeeded in establishing xenografts 
in athymic mice using fresh tumors from 
endometrial and ovarian cancer patients.  
One endometrial carcinoma underwent 
serial transplantation for more than 10 
passages.  Pathologic studies were 
conducted to compare tumor features 
among the original tumor and xenografts 
in mice and the morphology of the original 
patient tumors was generally preserved in 
xenografts.  
     The endometrial tumor described 
above was transplanted into 16 athymic 
mice and randomly divided into control 
and treatment groups, which were treated 
with raloxifene (Evista) at 
1.5mg/0.2ml/mouse through oral gavage 
daily (Monday through Friday) for 6 
weeks starting one week after tumor 
transplantation.  It was expected that the 
tumor would be responsive to raloxifene 
since the tumor abundantly expressed 
estrogen receptors (data not shown).  
Indeed the tumor sizes in the treatment 
group were significantly smaller than 
those of the control group at the first 3 
week during the treatment (t-test, p< 0.05, 
Fig. 1), indicating that this tumor was 
sensitive to raloxifene.  However, in the 
4th week after initiation of raloxifene, the 
tumor sizes in the two groups were not 
significantly different and showed the 
same growth rate, indicating that the 
tumor had developed resistance to 
raloxifene.  To investigate whether tumor 
heterogeneity could be a potential 
mechanism of drug resistance, we sought 
evidence for the existence of an 
inherently resistant subpopulation of 
cancer cells in the responsive tumor.    
 
 One untreated xenograft tumor was 
cultured and cancer cell clones were 
separated into culture dishes.  Nine 
clones were selected and each was 
grown to a population of 15 million cells.  
Each clone was injected separately into 3 
athymic mice and treated with raloxifene.  
We found that two clones were inherently 
resistant to raloxifene while other clones 
were sensitive to raloxifene (Fig. 2) when 
compared to the control.  This 
observation demonstrated the existence 
of cancer cell heterogeneity within a 
Defining Genetic Intra-Tumor Heterogeneity   5
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tumor in terms of the responsiveness to 
hormone therapy.  It suggested that intra-
tumor heterogeneity needs to be 
addressed for formulation of effective 
targeted therapies.  Since genetic 
mutations are at the root of tumor 
development, we next sought to 
determine whether intra-tumor 
heterogeneity can be defined according 
to genetic mutations in individual cancer 
cells.   
 
Figure 2.   
 Figure 1. 
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Figure 1.  Endometrial tumor response to 
raloxifene treatment. Y-axis: mean tumor 
cross-sectional areas (mm2). X-axis: weeks 
after treatment.  Raloxifene was given orally 
every day starting one week after tumor 
transplantation.  Means (n=6-8) and standard 
errors are presented.   
 
 
 
 
 Weeks of Treatment  
  Figure 2.  Clonal tumor response to 
raloxifene.  Xenografts were generated by 
clones (A3, C5, E4, E12, F2, F1, G8, H3 and 
H9) from the patient tumor and treated with 
raloxifene as above.  Y-axis: tumor cross-
sectional areas (mm2). X-axis: weeks after 
treatment.  Means (n=3) and standard errors are 
presented.
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2. SNP array for investigation of 
genetic alterations in the whole 
genome in cancer cells  
 
 A subcutaneous (sc) or intra-peritoneal 
(ip) xenograft created by injection of a 
patient tumor homogenate is unavoidably 
a mixture of many cell populations.  Since 
intra-tumor heterogeneity is our major 
concern, we used a cancer cell line, 
mixed or clonally selected, to test how a 
SNP array reports genotype information 
in a DNA from mixed cells.    
 
We ran a test to investigate the mutation 
rate in a clonally expanded cancer cell 
population using GeneChip Human 
Mapping 250K Nsp Array set from 
Affymetrix.  This gene array was able to 
detect changes in genotype in 262,264 
SNP sites in the cancer cell genome.  
The endometrial cancer cell line Hec50co 
was grown in cell culture dishes and 
harvested for extraction of DNA when 
total cell number reached approximately 
30 million.  A single cell was picked 
among the 30 million to start a new clonal 
expansion.  The starting parental 
Hec50co cell was designated as G0 and 
the sequential clonal passages (grown 
from a single cell from the previous 
generation) were named G1, G2 and G3, 
respectively (table 1).  Each generation 
needs approximately 25 divisions to 
reach 30 million from a single cell (225 ≈ 
3x107), assuming no cell death, in 4 
weeks (28 days).  The SNP array data 
showed that the number of LOH 
increased by 1626 from G1 to G3 (two 
generations).  Thus the rate of LOH is 
approximately 33 SNP sites/division or 29 
SNP sites/day.  This indicates that there 
is gradual accumulation of genetic 
mutations over time when cancer cells 
are grown in vitro.  However, we noticed 
that there was a decrease of LOH from 
the parental (G0) to G1 (15.26% to 
15.19%).  Since the parental cells (G0) 
could be a more mixed population of 
cancer cells than the clonally selected 
descendants (G1, G2 and G3), this 
decrease of LOH from G0 to G1 may be a 
false reading by SNP array data analysis.  
Indeed, the SNP array on the DNA 
specimen created by equally mixed DNAs 
from G1, G2 and G3 showed that the 
LOH is lower than any one of the 
individual DNAs (14.81% vs 15.19%, 
15.72% and 15.81%).  Thus, a 
heterogeneous mixture of DNA could 
present an increased heterogeneous 
reading (AB calls) or a reduced LOH 
reading.  After checking genotype 
readings in the individual SNP sites 
across the 3 generations and the mixture, 
we found that the reading in mixture DNA 
agrees with 90% of majority reading in 
G1, G2 and G3 (agrees with readings 
from 2 of 3 generations) and 10% goes 
with the minority reading (same as one of 
the 3 generations but not the other 2).  
This study suggests that we should be 
very careful in the interpretation of SNP 
array results from DNAs extracted from a 
tumor homogenate, which could be very 
heterogeneous in genetic mutations.   
 
3.  Genetic heterogeneity was 
demonstrated by SNP analysis in a 
tumor     
 
     In order to obtain clones representing 
subpopulations as distinct as possible, we 
transplanted part of the patient tumor as 
described in the raloxifene study into 
athymic mice to create many sc and ip 
xenografts.  DNA specimens from normal 
tissue from the same patient, one sc, and 
two ip tumors, were subjected to analysis 
by SNP array.  Ten DNA specimens from 
10 single cells (each of them from one ip 
tumor) were also used as a pure clonal 
Defining Genetic Intra-Tumor Heterogeneity   7
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DNA sources.  They went through whole 
genome amplification using a 
commercially available single-cell 
Omniplex whole genome amplification kit.  
The LOH data from these 13 specimens 
are shown at Table 2.  The LOH readings 
are markedly higher in single cells than 
those in tumor specimens.  The 
difference of LOH between any two 
specimens varied from 0.16% to 12.76%, 
suggesting a very heterogeneous nature 
in genetic mutations among cancer cells 
in the tumor.  This study suggests that 
survey of genetic alterations in the whole 
genome by SNP arrays could be a useful 
tool to document genetic profiles in 
individual cancer cells.   
 
4. The common genetic mutations 
among all cancer cells may be the 
earliest mutational events in cancer 
evolution: a strategy to profile genetic 
mutations in cancer stem cells  
 
     It is generally believed that 
differentiated normal cells (or adult stem 
cells) accumulate genetic mutations and 
thus transform into malignant cells (or the 
cancer stem cells), which expand to a 
population of billions of cancer cells in a 
tumor.  We reasoned that the genetic 
mutations in the cancer stem cell will be 
carried over to all their offspring, and, 
consequently, that the common genetic 
mutations shared by all cancer cells must 
have come from the cancer stem cell.  
Therefore, if we can isolate sufficient 
numbers of cancer cells, the common 
genetic mutations among them will give 
us a view of potential genetic mutations 
originating from the cancer stem cells.  
Among 59,582 informative SNP sites 
where the normal tissue had a 
heterozygous genotype, a matrix detailing
 
Table 1.  
Number of SNP Sites Percentage of Total SNP Sites Cell Data 
AA Call AB Call BB Call AA Call AB Call BB Call LOH 
Ref Genomic DNA 98218 69159 94887 37.45% 26.37% 36.18%
Hec50co cell (G0) 118491 29138 114636 45.18% 11.11% 43.71% 15.26%
Generation 1 (G1) 118438 29321 114505 45.16% 11.18% 43.66% 15.19%
Generation 2 (G2) 119435 27931 114872 45.54% 10.65% 43.80% 15.72%
Generation 3 (G3) 119330 27695 115239 45.50% 10.56% 43.94% 15.81%
Equal Mixed DNA 118150 30318 113797 45.05% 11.56% 43.39% 14.81%
 
SNP arrays on an endometrial cancer cell (G0), its clonally selected subsequent generations (G1, G2 and 
G3) and a DNA mixture equally from G1, G2 and G3.  AB calls at Ref Genomic DNA was used as 
standard and LOH of other specimens was derived by subtraction.   
 
genotypes of individual tumors and clones 
was generated for comparing the 
genotype in every SNP site among cancer 
specimens.  Data analysis showed that 
there were 797 out of 49,582 SNP sites 
displaying LOH in all cancer specimens (3 
tumors and 10 single cells), indicating that 
progenitor cells of the original patient 
tumor may possess genetic mutations in 
these regions.  We found that 797 LOHs 
have directly affected 4 exons from 4 
genes, 2 UTRs of 2 genes and 222 
introns of 189 genes, and the rest are in 
intergenic regions.  The 195 affected 
genes have been shown to play important 
roles in the following cellular functions: 
cellular adhesion and motility (14 genes), 
signal transduction (53), transcriptional 
regulation (21), transport (11), cellular 
metabolism (21), intracellular trafficking 
(8), RNA metabolism (7), cellular 
components (12), others (18) and 
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unknown (30).  While still far from 
determining what genetic mutations 
transform stem cells, this approach 
potentially provides a list of earliest 
genetic mutations involved in the 
malignant transformation.    
 
Table 2.  
 
 
 AB Calls among Total SNP Sites LOH 
Normal tissue 22.77%  
sc tumor 20.07% 2.70% 
Ip tumor 1 21.59% 1.18% 
Ip tumor 2 18.84% 3.93% 
Single cell clone 1 16.85% 5.92% 
Single cell clone 2 9.52% 13.25% 
Single cell clone 3 8.83% 13.94% 
Single cell clone 4 8.99% 13.78% 
Single cell clone 5 12.25% 10.52% 
Single cell clone 6 10.19% 12.58% 
Single cell clone 7 9.77% 13.00% 
Single cell clone 8 11.08% 11.69% 
Single cell clone 9 10.75% 12.02% 
Single cell clone 10 12.87% 9.90% 
 
 
SNP arrays on DNA specimens from the same patient tumor.  Percentage of LOH of cancer specimens 
was derived from subtraction of percentage of heterogeneous sites (AB calls) in tumor specimen by that 
in the normal tissue.   
 
 
5. Construction of phylogenetic tree to 
define genetic intra-tumor 
heterogeneity  
 
Inspired by genetic genealogies in 
population studies used to describe 
genetic relationships between individuals, 
we sought to construct a phylogenetic tree 
of cancer cells in a tumor in order to build 
a cancer evolutionary lineage based upon 
the similarity of genotypes in cancer cells.  
Based upon the genotype information 
from the 10 clones isolated from the 
tumor, we developed a phylogenetic tree 
using a neighbor joining method (Fig. 3).  
Nodes of the tree represent the inferred 
common ancestors of the genetic 
alterations.  As shown in Fig. 3, the tumor 
consists of 3 distinct subpopulations with 
Clone 10 belonging to the first, Clone 1 to 
the second, and the rest belonging to the 
third (Fig.3, the left panel).  An 
evolutionary history was extrapolated from 
identification of shared mutations.  For 
instance, the genetic mutations in Clone 3 
can be grouped into six sequential stages 
(Fig. 3, right panel).  Any genetic event at 
a higher step on this pathway occurs 
before the genetic event at a lower step.  
Analysis of a sufficient number of clones 
will allow us to determine the time course 
of all significant genetic mutations and 
build a virtual history of genetic evolution.
Defining Genetic Intra-Tumor Heterogeneity   9
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Figure 3.  
 
 Evolution History of Clone 3 
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Fig. 3. Quantitative description of genetic variations in subpopulations with chronological 
annotations.  The left panel shows a phylogenetic tree of the tumor.  The right panel illustrates the 
chronological order of genetic events in Clone 3 with arrows pointing the flow of time from the past to the 
present.  Any genetic event at a higher step would have to occur before the genetic events at a lower 
step.  Addition of more clones to the tree will increase the resolution to determine the physical distribution 
of genetic events in clones and their evolution history.    
 
Discussion  
 
We have developed a genealogical 
approach, similar to 
anthropological/paleontological research, 
for reconstructing cancer evolutionary 
history and revealing the chronology of 
oncogenic processes.  Instead of taking a 
tumor as one entity and using DNA from 
mixed cells, we isolated single cell clones 
to deconstruct the tumor.  Theoretically, 
our approach will be able to differentiate 
genetic alterations occurring at the single 
mutations acquired every division as long 
as the cell lineage carrying a specific 
mutation is preserved in the subsequent 
evolution and cancer expansion.  Our 
approach is logical for examining whether 
there is a common mutational pathway 
among tumors because it starts with the 
elucidation of the genetic pathway in an 
individual tumor, and is thus independent 
of whether there is a common genetic 
pathway among tumors grouped 
according to histology or genetic features.  
In another words, it may allow discovery 
cell ancestry from the new genetic of a common mutational pathway existing 
Defining Genetic Intra-Tumor Heterogeneity   10
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in different types of tumors.   
 
We reported here that the earliest genetic 
utations may involve some of the 797 
l technical 
urdles to be addressed before fully 
l hurdle will be the 
olation of a sufficient number of pure 
truct a phylogenetic tree 
sing the genomic SNP data from the ten 
m
SNP sites.  This approach will allow us to 
identify the earliest genetic mutations and 
possibly those responsible for the 
malignant transformation of stem cells 
without a need to isolate cancer stem 
cells, which commonly has to rely on 
certain cell surface markers.    
 
However, there remain severa
h
realizing the potential of this strategy.  
The first will be the requirement of 
complete documentation of genetic 
alterations in the whole genome.  Using 
SNP arrays has some drawbacks, even 
with the arrival of higher resolution chips 
such as 1 million SNP sites per array.  
The SNP array we used interrogates a 
base sequence every 10-20K and it will 
surely miss many alterations between two 
SNP sites such as point mutations, which 
are reported to be more common than 
other genetic alterations in cancer6,20.  
Interestingly, a recent report shows that 
LOH in stem cells is much more common 
than point mutations after exposure to a 
carcinogen, and LOH could be an 
important mechanism of carcinogen-
induced oncogenesis in stem cells.21  
Additionally, LOH is a common 
mechanism for loss of function in tumor 
suppressor genes.  Thus, SNP arrays to 
detect LOH may be particularly useful in 
the detection of genetic alterations in 
cancer stem cells.    
 
The second technica
is
cancer cell clones to represent the 
heterogeneity of the original tumor.  A 
small piece of tumor, even isolated under 
microscope, may include many genetically 
distinct cells, which will distort the linkage 
analysis and generation of a phylogenetic 
tree.  Isolation of a single cell is preferred 
because it has only one set of the 
genome without any potential 
heterogeneity.  However, the quality of 
genomic DNA from a single cell may pose 
a problem for genomic analysis.  In our 
study, the call rate in SNP arrays is 
significantly lower in the DNA from a 
single cell genome than that from a tumor.  
This may result from loss of SNP sites 
during amplification of a single copy 
genome.  The potential solution will be to 
select a group of homogeneous cells.  
Here, we chose to select only one cell 
from every xenograft tumor in order to 
make these single cells as distinct from 
each other as possible.  There is also a 
possibility that the genetic alterations 
observed in cells are acquired during 
tumor growth in athymic mice.  There will 
be new genetic alterations when cancer 
cells proliferate.  It is certain that cancer 
cells acquire a significant amount of 
genetic alterations during their xenograft 
growth.  If the theory of genetic instability 
for oncogenesis bears out, there will be 
an exponential increase in genetic 
mutations and those responsible for early 
tumor development will be overwhelmed 
by new mutations.  However, these more 
recently acquired genetic mutations 
should be located at the bottom part of 
our phylogenetic tree and the number of 
newly acquired genetic alterations during 
xenograft growth should not exceed the 
difference between clones 9 and 3 (or the 
least of differences between any two 
clones) since any xenograft used in the 
building of our phylogenetic tree was 
generated by injection of patient tumor 
homogenates.   
 
In order to cons
u
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clones, we mapped SNP character 
information onto corresponding DNA 
strings.  This facilitated the use of existing 
phylogenetic software tools previously 
developed for DNA sequence data, as 
described below.  To the best of our 
knowledge, this represents the first 
attempt to develop a clonal phylogenetic 
reconstruction based on SNP data 
reported in the literature.  We have used 
the neighbor-joining (NJ) clustering 
method,17 which is widely regarded as 
one of the best approaches available for 
computing phylogenies.19 It is fast and 
has demonstrated good accuracy in many 
test problems. The initial reconstruction 
reported here can be further refined in 
several important ways.  Continuing work 
is aimed at establishing the statistical 
robustness of the candidate 
reconstruction using bootstrap methods,22 
and comparing it with the results of 
alternative methods of phylogenetic 
reconstruction, such as Bayesian Markov 
Chain Monte Carlo (MCMC) and 
coalescent theory.  These studies will 
enable us to investigate consistency and 
stability across alternative reconstructed 
clonal phylogenies and develop a final 
consensus reconstruction for the given set 
of clones, including reliability estimates for 
various branches, as well as providing 
guidance for future experiments with 
respect to tolerable levels of noise, and 
quantifying the impact of additional clonal 
samples on the final consensus 
genealogy.  
 
Since our aim in the present study is to 
lustrate a general experimental/modeling 
ced a new 
oncept in cancer biology: a temporal 
il
strategy for the reconstruction of cancer 
clone genealogies, Fig. 3 should not be 
construed as a definitive phylogenetic 
reconstruction for the ten clones studied 
here.  Further computational analysis will 
be needed in order to fully explore the 
effects on the final reconstructed cancer 
cell phylogeny of algorithmic choices such 
as the choice of distance measure or the 
treatment of missing data, as well as 
underlying model assumptions relating to 
the nature of character transformations, 
and the effects of experimental noise in 
the SNP data.  For the NJ method, 
parallelized bootstrap resampling23 may 
be used to compute statistical bounds and 
provide reliability assessments for all or 
parts of the reconstructed tree.24  Other 
phylogenetic reconstruction methods, 
while algorithmically complex and 
computationally demanding, represent 
valuable complementary approaches to 
clustering methods such as NJ.  
Examples include maximum-likelihood 
inference using Markov Chain Monte 
Carlo sampling25 and coalescent theory. 
26 These methods incorporate a principled 
mechanism for aggregating the results of 
randomly sampled candidate tree 
structures, along with an underlying 
parametric evolutionary model that 
provides an intrinsic molecular clock.  
Investigation of these algorithms and their 
impact on the final phylogenetic 
reconstruction for the set of ten cancer 
clones is presently underway. 
 
Our study method has introdu
c
description of genetic events in cancer 
development.  With the development of 
affordable whole genome sequencing 
technology, we should be able to more 
thoroughly understand the genetic basis 
of cancer.  Definition of GITH through 
quantitative description of genetic 
variations among subpopulations and 
chronological annotations of these events 
will significantly improve our 
understanding of tumor progression and 
assist in predicting the outcome of cancer 
therapies. 
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